Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications

Michael G. Buontempo; Bianca T. Santos

doi:10.1111/jdv.20512

journal article Jan 24, 2025

Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications

Michael G. Buontempo

Bianca T. Santos

Journal of the European Academy of Dermatology and Venereology Vol. 39 No. 2 pp. 263-264 · Wiley

View at Publisher Save 10.1111/jdv.20512

Topics

No keywords indexed for this article. Browse by subject →

References

5

[1]

10.1016/j.jaad.2023.04.022

[2]

10.1111/jdv.20197

[3]

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John P.H. Wilding, Rachel L. Batterham, Salvatore Calanna et al.

New England Journal of Medicine 10.1056/nejmoa2032183

[4]

10.1016/j.regpep.2006.02.007

[5]

10.1007/s11695‐021‐05311‐2

Metrics

8

Citations

5

References

Details

Published: Jan 24, 2025
Vol/Issue: 39(2)
Pages: 263-264
License: View

Authors

M

Michael G. Buontempo

Department of Internal Medicine Ocean University Medical Center Brick Township New Jersey USA

B

Bianca T. Santos

Department of Medicine Sciences University of New England College of Osteopathic Medicine Biddeford Maine USA

Cite This Article

Michael G. Buontempo, Bianca T. Santos (2025). Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications. Journal of the European Academy of Dermatology and Venereology, 39(2), 263-264. https://doi.org/10.1111/jdv.20512

Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications

You May Also Like